[1] |
CHEN Zhiwen, WANG Longrong, WANG Lu.
Current status and progress of targeted therapy for hepatocellular carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 171-182.
|
[2] |
LEI Guojie, YU Yanhua, LIU Yingchao, BIAN Wenxia, DU Jing, TONG Xiangmin.
Mechanism of PX-12 induced apoptosis of hepatocellular carcinoma cells through oxidative stress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 961-967.
|
[3] |
LAN Xueling, HUANG Yanni, ZHU Minmin, MA Ping, DONG Min.
Advances of VEGF signalling pathway in hepatocellular carcinomar invasion and metastasis and therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 707-714.
|
[4] |
WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei.
Mechanism of DCLK1 transcriptional regulation in HCC
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
|
[5] |
DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli.
Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
|
[6] |
YE Kaili, ZHENG Wen, YE Qifa, YANG Lan .
Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
|
[7] |
YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie.
Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
|
[8] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|
[9] |
DING Xueming, CHEN Tianpeng, XU Qiang, HE Huan, HE Ming.
Tetramethylpyrazine attenuates doxorubicin induced cardiotoxicity through 14-3-3γ/Bcl-2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 361-367.
|
[10] |
HUANG Kang, LI Ling, YE Qifa, PENG Guizhu.
Expression of long non-coding RNA LINC00844 in hepatocellular carcinoma and its inhibiting effect on cell proliferation and migration
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 366-372.
|
[11] |
CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo.
Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.
|
[12] |
YANG Shucai,ZHANG Li,LIU Liping,DENG Weijie,ZHOU Jie,LIU Hui,ZHANG Baohu,JIN Tao.
Effect of hypoxia-inducible factor 2α on chemoresistance of hepatocellular carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 630-636.
|
[13] |
TIAN Jing, MENG Qiuhua, LIANG Qiuyun, DONG Min.
Research progress in the associations of metabolic diseases and therapeutic drugs with hepatocellular carcinomas
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 103-110.
|
[14] |
LIU lei, LI Yixiao, WAN Bo, ZENG Qing.
miR-200c induces resistance to doxorubicin through the Wnt/beta-catenin signaling pathway in bladder cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 510-516.
|
[15] |
YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun.
Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
|